ArticleEndocrine2026
Thyroid hormone therapy initiation after hemithyroidectomy: treatment burden, timing, and predictors in a population-based cohort.
Article in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo determine the two-year burden, timing, and predictors of thyroid hormone therapy initiation after hemithyroidectomy in previously euthyroid adults.
methodsRetrospective population-based cohort study using de-identified electronic health record data from Clalit Health Services (2003-2020), extracted through the MDClone research platform. Adults undergoing hemithyroidectomy with preoperative TSH < 5.0 mIU/L, no preoperative thyroid hormone therapy, and at least two years of follow-up were included. The primary endpoint was first levothyroxine dispensing or overt biochemical hypothyroidism within 24 months.
resultsAmong 8,467 eligible patients, 3,362 (39.7%) reached the endpoint within 24 months: 2,179 (25.7%) by 4 months and 3,100 (36.6%) by 12 months. Extended follow-up identified 558 additional initiations (cumulative 46.3%). Treatment initiation was markedly higher among patients with thyroid cancer (72.7%) than those without (33.4%). The strongest multivariable predictors were preoperative TSH (OR 1.55 per 1 mIU/L; 95% CI, 1.47-1.64) and thyroid cancer (OR 4.99; 95% CI, 4.29-5.81).
conclusionThyroid hormone therapy initiation is common after hemithyroidectomy, affecting nearly 40% of previously euthyroid adults within two years. Preoperative TSH and thyroid cancer identify high-burden subgroups and should inform preoperative counseling when hemithyroidectomy is chosen to preserve endogenous thyroid function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.